ME is a deeply complex disease with many different causes and risk factors.
In over 30 years of global research into the disease, not a single replicable genetic finding had been reported until now.
We have for the first time identified some of the different genetic mechanisms causing ME/CFS and used this to stratify patients.
We’re currently replicating our results in a much larger, better characterized patient population, using thee DecodeME study data as part of the LOCOME (Long Covid and ME) grant supported by Innovate UK.
We're now conducting research to:
- Validate simple saliva/blood genotyping tests for ME/CFS and long COVID
- Identify actively protective biology that may prevent people getting ME or help them to recover
- Identify and validate drug repurposing candidates that may be able to treat ME patients
On this page, we've collated recent papers, posters, videos and blogs, about our ME/CFS and long COVID research.
Progress Summary |
Poster |
|
Beginning to Unravel the Biological Drivers of ME Overview of our recent ME/CFS and long Covid research and the clinical validation of new therapeutics and diagnostic tests. |
Identifying Genetic Risk Factors for ME/CFS and Long COVID Poster detailing our discovery of the first genetic associations, novel targets, actively protective biology, and diagnostics. |
 |
 |
Papers |
|
|
|
Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis |
 |
 |
|
|
 |
Blog |
|
New Study Links 14 Genes to ME/CFS |
|
 |
About PrecisionLife
PrecisionLife is a pioneering precision medicine company changing the way the world predicts, prevents, and treats complex, chronic diseases by finding better, more personalized diagnostic and treatment options for patients.
Our platform is unique in its ability to identify causal biology and link chronic disease patients to effective treatments via the molecular mechanism of their disease or drug response. These insights enable us to significantly improve probabilities of success across the biopharma and healthcare value chain.
We discover new subgroups of patients with mechanism-based patient stratification biomarkers, identify novel treatment opportunities for unmet medical needs, de-risk and accelerate clinical trials, find new applications for existing drug programs, and build highly predictive complementary diagnostics, personalized risk prediction and disease prevention tools.
We’re working in collaboration with some of the largest global biopharma companies and have a proven, responsive
and cost-effective way of contracting and working with our partners which recognizes, respects and complements their
existing team’s expertise and processes.
Contact us via the form below to find out more about partnering with PrecisionLife.